ERBB2 and breast carcinoma: Some kinase inhibitors have been approved for anti-cancer therapies, for example, BCR–ABL inhibitors have been approved for chronic myeloid leukemia [20], BRAF inhibitors have been approved for melanoma [21] and HER2 (also known as ERBB2) inhibitors have been approved breast cancer [22].